GlobeNewswire

Aldevron Now Utilizing Berkeley Lights' Beacon® Platform

Share

Launches Advanced Single B-Cell Platform to Help Speed Up Screening Process, Antibody Discovery

Fargo, N.D., June 11, 2019 (GLOBE NEWSWIRE) --

Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic platform (Beacon) to support rapid execution of species agnostic single B-cell antibody discovery to complement its industry-leading genetic immunization and hybridoma capabilities. The Beacon platform will be located in the recently announced expansion lab space in Aldevron’s Freiburg, Germany, facility and will be coming on-line in June 2019.

The Beacon platform, created by Berkeley Lights, Inc, is uniquely designed to carefully and specifically isolate, monitor and assay almost any cell type. When used for antibody discovery, the Beacon platform can isolate and identify functional antibody-producing B-cells in less than one day, eliminating weeks of work. Once individual target cells are identified, the cells can be exported for sequencing or cloning. Each cell is tracked so that the phenotype can be linked to the genotype.

“Adding the Berkeley Lights Beacon platform is a key component to our antibody discovery service and to our clients,” said Aldevron’s President of its Antibody Business Unit, Brian Walters. “The rapid screening and assay functionality will allow our team to generate rare antibodies against difficult targets and provide multiple approaches to support the antibody development objectives of our clients and the industry with a royalty free, fee-for-service option.”

“Berkeley Lights’ digital cell biology platform offers the diversity, applicability, and agility to meet the demands of today’s changing landscape of antibody discovery, “said Dr. Eric Hobbs, Chief Executive Officer at Berkeley Lights. “We are pleased Aldevron is joining our growing list of companies incorporating the Beacon platform to accelerate drug discovery. “

Aldevron’s Freiburg location focuses on antibody discovery and development becoming the company’s second site and first European site in 2004. Industry leading genetic immunization expertise combined with expanded cell culture, fusion and sequencing capabilities, and the, new single B-cell platform, have positioned Aldevron to offer comprehensive antibody services from target identification through large-scale pre-clinical production.

About Aldevron
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-SourceTM quality system. Aldevron recently announced its 14-acre campus expansion plan for its headquarters in Fargo, North Dakota; and has additional facilities in Madison, Wisconsin, and Freiburg, Germany. To learn more, visit www.aldevron.com.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor20.8.2019 17:45:00 CESTPress release

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035 This patent strengthens the protection of lanifibranor in the United States Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protect

PCI Biotech: Invitation to second quarter and first half 2019 results presentation20.8.2019 15:38:00 CESTPress release

Oslo, Norway, 20 August 2019 - PCI Biotech invites to a presentation of the company's second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 28 August 2019. For further information, please contact: Ronny Skuggedal, CFO Email: rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutica

Regarding resignation of member of the Supervisory Board20.8.2019 15:30:00 CESTPress release

We hereby inform that, T. Lukoševičius, a member of Supervisory Board of AB Klaipedos nafta (hereinafter – the Company) 20 August 2019 submitted a notice of resignation of members of Supervisory Board of the Company as of 3 September 2019 (this day is the last day of the mandate). It should be noted that, currently the Supervisory Board of the Company consists of 3 members, 2 of them are independent. After the resignation of T. Lukoševičius, the Ministry of Energy of the Republic of Lithuania will conduct the selection of new member of the Supervisory Board. The Supervisory Board is elected by the General Meeting of Shareholders for 4 years. If individual members of the Supervisory Board are elected, they shall be elected only until the end of the term of office of the current Supervisory Board. Jonas Lenkšas, Chief Financial Officer,+370 694 80594

SERSTECH AB: Boardmember Anna Werntoft resigns from the Board of Serstech20.8.2019 13:40:00 CESTPress release

Anna Werntoft will leave the board of directors effective on the 30th of September. The reason for her resignation is that she enters a new operational position with terms that does not allow external assignments. Serstech wishes Anna all the best in her new position and would like to thank her for her contribution while being on the Serstech Board. The Serstech will consist of three Board members until the vacant position is filled. The search for a replacement has started and will be concluded before the next annual general meeting. For further information, please contact: Stefan Sandor, CEO, Serstech AB tel: +46 739 606067 email: ss@serstech.com Thomas Pileby, Chairman of the Board, Serstech AB tel: +46 702 072643 email: tp@serstech.com Company website: www.serstech.com The information was submitted for publication, through the agency of the contact person set out above at 13:40 CET on August 20, 2019. Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-2